

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

Altered increase in STAT1 expression and phosphorylation in severe COVID-19

Hector Rincon-Arevalo^{1,2,3,4+}, Arman Aue^{1,2,3+}, Jacob Ritter^{2,6}, Franziska Szelinski^{2,3}, Dmytro Khadzhynov¹, Daniel Zickler¹, Luisa Stefanski², Andreia C. Lino³, Sixten Körper⁵, Kai-Uwe Eckardt¹, Hubert Schrezenmeier⁵, Thomas Dörner^{2,3+} and Eva V. Schrezenmeier^{1,2,6+}

¹Department of Nephrology and Medical Intensive Care, Charité- Universitätsmedizin Berlin, Berlin, Germany.

²Department of Rheumatology and Clinical Immunology, Charité- Universitätsmedizin Berlin, Berlin, Germany.

³Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany.

⁴Grupo de Inmunología Celular e Inmunogenética, Facultad de Medicina, Instituto de Investigaciones Médicas, Universidad de Antioquia UdeA, Medellín, Colombia.

⁵Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm; and Institute of Transfusion Medicine, University of Ulm

⁶Berlin Institute of Health (BIH)

+these authors contributed equally.

Corresponding Author:

Eva V. Schrezenmeier, MD

Department of Nephrology and Medical Intensive Care, Charité- Universitätsmedizin Berlin, Berlin, Germany.

Chariteplatz 1, 10117 Berlin, Germany

Email: eva-vanessa.schrezenmeier@charite.de

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

38 Abstract

39 The interferon pathway represents a key antiviral defense mechanism and is being considered
40 as a therapeutic target in COVID-19. Both, substitution of interferon and blocking interferon
41 signaling through JAK STAT inhibition to limit cytokine storms have been proposed. However,
42 little is known so far about possible abnormalities in STAT signaling in immune cells during
43 SARS-CoV-2 infection. In the current study, we investigated downstream targets of interferon
44 signaling, including STAT1, pSTAT1 and 2 and IRF1, 7 and 9 by flow cytometry in 30 patients
45 with COVID-19, 17 with mild and 13 with severe infection. We report an upregulation of STAT1
46 and IRF9 in mild and severe COVID-19 cases, which correlated with the IFN-signature
47 assessed by Siglec-1 (CD169) expression on peripheral monocytes. Most interestingly, Siglec-
48 1 and STAT1 in CD14+ monocytes and plasmablasts showed lower expression among severe
49 COVID-19 cases compared to mild cases. Contrary to the baseline whole protein STAT1
50 expression, the phosphorylation of STAT1 was enhanced in severe COVID-19 cases,
51 indicating a dysbalanced JAK STAT signaling that fails to induce transcription of interferon
52 stimulated response elements (ISRE). This abnormality persisted after IFN- α and IFN- γ
53 stimulation of PBMCs from patients with severe COVID-19. The data suggest impaired STAT1
54 transcriptional upregulation among severely infected patients which may represent a potential
55 predictive biomarker and may allow stratification of patients for certain interferon-pathway
56 targeted treatments.

57

58 1. Introduction

59

60 Following viral infection, a complex regulatory system of innate and adaptive immune
61 mechanisms is initiated to defend against viral invasion. One of many responses to viral
62 infection is the induction of the pleiotropic cytokine interferon (IFN) [1]. It acts as a key link
63 between the innate and adaptive immune system. IFN- α (type I IFN) is mainly secreted by
64 plasmacytoid dendritic cells (pDCs), while IFN- γ (type II IFN) is predominantly produced by
65 natural killer cells and by certain T cells and macrophages. Both, type I and type II IFN, have
66 diverse but complementary antiviral effects such as induction of apoptosis and activation of
67 macrophages, natural killer (NK) cells as well as B and T lymphocytes [2, 3].

68 Regarding severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection, IFN
69 related antiviral response attracted attention since inborn errors of type I IFN and the presence
70 of autoantibodies against type I IFN were found to be associated with a severe course of the
71 disease [4, 5]. Roughly 10% of coronavirus disease 2019 (COVID-19) patients with severe
72 pneumonia produce neutralizing autoantibodies against IFN α , IFN ω , or both, while patients
73 with no or mild disease have no detectable autoantibodies [4]. Further, it has been shown that
74 patients with severe COVID-19 have a highly impaired IFN type I signature, with reduced IFN-
75 α production and activity [6].

76 Type I IFNs signal through Janus kinase (JAK) and signal transducer and activator of
77 transcription (STAT) pathway and thereby stimulate gene expression. After specific binding to
78 the IFN- α receptor (IFNAR), consisting of two chains (IFNAR1 and IFNAR2),
79 autophosphorylation of the newly formed complex leads to phosphorylation of the receptor-
80 associated JAK1 and TYK2 [7, 8]. Subsequently, further phosphorylation of cytoplasmic
81 STAT1 and STAT2 induces its dimerization and interaction with IFN regulatory factor 9 (IRF9),
82 a strong enhancer of translocation to the nucleus [9-11]. The activation of STAT1 is achieved
83 by tyrosine phosphorylation on Y701 that is followed by nuclear accumulation [12].

84 Formation of a complex called interferon-stimulated gene factor 3 (ISGFR3) binding to IFN-
85 stimulated response elements (ISRE) finally results in stimulation of gene expression [12].
86 Likewise the same sequence of biochemical processes leads to the transcriptional influence
87 of IFN- γ (type II IFN), involving the IFN- γ receptor (IFNGR), JAK1 and JAK2, and dimerization
88 of the homodimer STAT1 binding to IFN- γ -activated site (GAS) [1]. Figure 1A schematically

89 depicts JAK/STAT signaling. Although it has been shown that the virus proteins NSP5,
90 ORF7a, N and ORF6 are able to directly interfere with JAK STAT signaling by inhibiting
91 translocation of STATs or inhibiting their phosphorylation in SARS-CoV-2 infected cultured
92 cells [13, 14], it is not fully understood how JAK STAT signaling is altered in immune cells and
93 if a dysbalance in JAK STAT signaling may contribute to disease severity.

94 Here we report an increased STAT1 expression in mild and severe COVID-19 patients
95 compared to controls. Severe COVID cases showed lower STAT1 expression than mild
96 patients, accompanied by elevated phosphorylation of STAT1 at the pY701 phosphosite
97 suggesting a disturbance of signal transduction related to impaired STAT1 transcription, which
98 is not surmountable by additional IFN stimulation.

99

100 **2. Methods**

101

102 **2.1. Study participants**

103

104 Peripheral blood samples (EDTA anti-coagulated, BD vacutainer system, BD Diagnostics,
105 Franklin Lakes, NJ, USA) from 20 healthy controls and 30 COVID patients were analyzed, 17
106 with mild (WHO 8-point ordinal scale 1 and 2) and 13 with a severe course of the disease
107 (WHO 8-point ordinal scale ≥ 4) [15]. Donor information is summarized in Table 1. Severe
108 cases were participants in the CAPSID trial that investigated convalescent plasma therapy
109 (EudraCT2020-001210-38; NCT04433910). Samples for this study were collected at baseline
110 prior to administration of the investigation drug. All participants or their legal representatives
111 gave written informed consent according to the approval of the ethics committee at the Charité
112 University Hospital, Berlin (EA2/066/20 Pa-Covid-19 and University of Ulm (CAPSID trial
113 (115/20 and 488/20) [16, 17].

114

115 **2.2. Analytical methods and flow cytometry**

116

117 Intracellular phenotyping of STAT1, pSTAT1, pSTAT2, IRF1 and IRF7 levels in B and T cells
118 was conducted as previously published [18]. Briefly, peripheral whole blood (500 μ l) was lysed
119 and fixed the same day of acquisition using 5 ml BD Phosflow Lyse/Fix Buffer (BD Biosciences,
120 San Jose, CA, USA, 10 min, 37°C) considering the manufacturer's protocol (mix of 1:5 in aqua
121 dest). After two washing steps using ice-cold PBS Dulbecco (Biochrom GMBH, Berlin,
122 Germany) (530 g, 8 min, 4°C), permeabilization was performed using 200 μ l BD Perm Buffer
123 II (BD Biosciences, San Jose, CA, USA; 12h, -20°C), followed by overnight storage at -20°C.
124 Next, cells were washed twice with PBS Dulbecco containing 0.5% BSA/EDTA (530 μ g, 8 min,
125 4°C) and resuspended in 50 μ l of PBS with 20% Brilliant Buffer (BD Horizon, San Jose, CA,
126 USA). After incubation with 2.5 μ l of FcR blocking reagent (Miltenyi Biotec Bergisch Gladbach,
127 NRW, Germany) for 5 min, staining for 1 h and subsequent flow cytometry analysis were
128 carried out at the same day.

129 All flow cytometry analyses were performed using a BD FACS Fortessa (BD Biosciences,
130 Franklin Lakes, NJ, USA). To ensure comparable mean fluorescence intensities (MFIs) over
131 time of the analyses, Cytometer Setup and Tracking beads (CST beads, BD Biosciences,
132 Franklin Lakes, NJ, USA) and Rainbow Calibration Particles (BD Biosciences, Franklin Lakes,
133 NJ, USA) were used. For flow cytometric analysis, the following fluorochrome-labeled
134 antibodies were used: BUV395 anti-CD14 (BD, clone M5E2, 1:50), PE-Cy7 anti-CD3 (BD,
135 clone UCHT1, 1:100), BV510 anti-CD4 (BD, clone SK3, 1:50), BUV737 anti-CD8 (BD, clone
136 SK1, 1:500), BV711 anti-CD19 (BD, clone SJ25C1,1:25), BV421 anti-CD20 (BD, clone 2H7,
137 1:25), BV786 anti-CD27 (BD, clone L128, 1:50), PE-CF594 anti-IgD (Biolegend, San Diego,
138 CA, USA, clone IA6-2, 1:500) for basic immunophenotyping of cell populations of interest.
139 Quantitative analysis was done using the following intracellular fluorochrome-labeled
140 antibodies: PE anti-STAT1 (BD, clone 1/Stat1, 1:10), FITC anti-pSTAT1 (BD, clone 4a, 3:20),
141 AF647 anti-pSTAT2 (R&D Systems, clone 1021D, 1:5), PE anti-IRF1 (BD, clone 20/IRF-1,
142 1:20), AF647 anti-IRF7 (BD, clone K47-671, 1:10). For IRF9 analysis an unconjugated IRF9
143 antibody (Thermo Fisher, isotype rabbit IgG, clone 14H9L22, 1:100) was applied. After staining

144 and washing cells, a secondary antibody was used for specific binding of IRF9 (Jackson
145 Immuno Research, isotype donkey anti rabbit IgG, polyclonal, 1:100). Number of absolute B
146 cells was measured with Trucount (BD) and samples were processed according to the
147 manufacturer's instruction. As a control, at least one healthy control sample was processed
148 simultaneously with patients' samples. Siglec-1 (CD169) expression analysis on CD14+
149 monocytes was performed at baseline as previously described [19].

150 **2.3. Isolation of peripheral blood mononuclear cells (PBMCs)**

151
152 Peripheral blood mononuclear cells (PBMCs) were obtained by density gradient centrifugation
153 using Ficoll-Paque PLUS (GE Healthcare Bio-Sciences, Chicago, IL, USA).

154 **2.4. Functional analysis of IFN α and IFN γ signaling pathways**

155
156
157 In order to evaluate the functional cellular responsiveness upon IFN stimuli, stimulation
158 experiments were carried out as previously described [18]. In brief, we suspended isolated
159 PBMCs in RPMI medium (GlutaMAX, Life Technologies, Paisley, UK) and stimulated with
160 IFN α 2a (100 ng/ml for 5 min and 5 ng/ml 48h) (Recombinant Human, Milteny, Germany) or
161 IFN γ 1b (100 ng/ml for 5 min and 5 ng/ml 48h) (Recombinant Human, Milteny, Germany). Cells
162 were then harvested, washed, lysed, permeabilized and stained using the same staining as
163 mentioned above followed by flow cytometry.

164 **2.5. Statistical analysis**

165
166
167 Flow cytometry data were analysed using FACSDiva software (Becton Dickinson, Franklin
168 Lakes, NJ, USA) and FlowJo (version 10, TreeStar, Ashland, OR, USA). For graphical and
169 statistical analysis, GraphPad Prism (version 7.00, GraphPad Software, La Jolla, CA, USA)
170 was used. Mann–Whitney tests were used for the comparison of two groups. For multiple group
171 comparison, two-way ANOVA with Šidák's post-test for multiple comparison. Spearman
172 correlation coefficient was calculated to detect possible associations between parameters or
173 disease activity, respectively. P-values < 0.05 were considered significant. Correlation matrix
174 was calculated using base R and corrplot package (R Foundation for Statistical Computing)
175 using Spearman method.

176 **3. Results**

177 **3.1. Cohort characteristics**

178
179
180
181 In the current cohort, we included 17 out-patients with mild COVID-19 during their quarantine
182 (WHO 8-point ordinal scale 1 and 2) and 13 hospitalized patients treated for severe COVID-
183 19 pneumonia on an Intensive Care Unit (ICU) (WHO 8-point ordinal scale ≥ 4) (Table 1) [15].
184 Age and days post symptom onset were not significantly different between both groups, while
185 more patients with mild COVID-19 were female. Among patients with severe disease
186 manifestation, 6 patients subsequently died because of COVID-19.

187 **3.2. Reduced STAT1 expression in patients with severe COVID-19**

188
189 Since severe COVID-19 has a highly impaired IFN type I signature, with especially reduced
190 IFN- α production and activity [20], we initially asked how the major effector downstream targets
191 of type I IFN are affected among patients with COVID-19. We found a significantly increased
192 STAT1 protein expression in all analyzed cell subsets from whole blood analysis, including T
193 cells (CD4⁺ and CD8⁺), B cells (IgD⁺CD27⁻ (Naïve), IgD⁺CD27⁺ (PreSwitch), IgD⁻CD27⁺
194 (PostSwitched) and IgD⁻CD27⁻ (Double Negative, DN)), plasmablasts (CD20^{low}CD27^{high}) and
195 monocytes (CD14⁺) from all patients with COVID-19 compared to healthy controls (Figure 1
196 C-E). Most notably, reduced STAT1 was observed in severe COVID-19 cases compared to

197 mild COVID-19 cases in particular in CD14⁺ monocytes and plasmablasts, respectively (Fig
198 1D and Fig 1E).

199 Since STAT1 signaling is mainly regulated through phosphorylation, we were interested in the
200 phosphorylated form of STAT1. Baseline pSTAT1 was significantly increased in monocytes,
201 CD4⁺ and CD8⁺ T cells, pre-switched B cells (IgD⁺CD27⁺) and plasmablasts from severe
202 COVID-19 patients compared to healthy controls (Figure 1F-H).

203 To better understand the relation between the expression of full protein STAT1 and
204 phosphorylated protein (pSTAT1), the ratio of pSTAT1/STAT1 was obtained. A reduced ratio
205 of pSTAT1/STAT1 was observed in plasmablasts and CD14⁺ cells from COVID-19 patients
206 with mild disease compared to those with severe disease (Figure S1A). No differences in
207 pSTAT2 levels were observed among study groups (Figure S1B). These results suggest that
208 mildly affected COVID-19 patients increased their STAT1 expression, but not their detectable
209 levels of phosphorylation, while severely affected COVID-19 patients showed a greater
210 increase of phosphorylation in relation to the increase of total STAT1 expression. Thus, there
211 is a substantial impairment to increase STAT1 transcription in severe COVID-19 that especially
212 affects CD14⁺ monocytes and plasmablasts.

213 **3.3. Reduced IRF9 expression in patients with severe COVID-19**

214
215 STAT1 is part of interferon mediated viral response, representing a key component of
216 complexes like ISGF3 and GAS, responsible for amplified interferon-mediated signals [12]. To
217 better understand the nature of STAT1 alteration in patients with COVID-19, IRF9
218 (components of ISGF3 and GAS complexes) was evaluated. An increased IRF9 expression
219 was found in CD8⁺ T cells, IgD⁺CD27⁻, IgD⁺CD27⁺, IgD⁻CD27⁺ and IgD⁻CD27⁻ B cells, PB and
220 CD14⁺ cells from patients with mild COVID-19 compared to healthy controls (Fig. 2B, C).
221 Similar to STAT1, severe COVID-19 was characterized by reduced IRF9 expression compared
222 to mild COVID-19, in PB and CD14⁺ cells (Figure 2 A-C). Patients with severe COVID-19 had
223 lower IRF9 expression compared to mild cases, consistent with a reduced STAT1 expression.
224 Regarding the expression of IRF1, a molecule well known to directly bind and impact the ISRE
225 [12], we found no difference between healthy controls and patients with COVID-19 irrespective
226 of severity in T cells, and IgD⁺CD27⁻, IgD⁺CD27⁺, IgD⁻CD27⁺ and IgD⁻CD27⁻ B cells while in
227 CD14⁺ monocytes and plasmablasts, IRF1 was significantly increased among patients with
228 mild or severe COVID-19 compared to healthy controls (Fig. 2 D-F).
229 Expression of intracellular phosphorylated (pS477/pS479) IRF7 did not significantly differ
230 between all groups studied and between the different T and B cell populations (Fig. 2 G-I).
231 Only in monocytes, IRF7 was reduced in severely affected COVID-19 patients compared to
232 mild cases and healthy controls.

233 234 **3.4. Correlation of STAT1 with IFN signature**

235 We wondered how these findings interrelate especially with regard to the IFN- signature, which
236 was assessed by the expression of the surrogate marker Siglec-1 (CD169) on monocytes [20].
237 In our cohort we observed a significant reduction of Siglec-1 expression in severely affected
238 COVID-19 patients (Figure 3A). Siglec-1 and STAT1 showed a significant correlation with in
239 CD3⁺ T cells, CD19⁺ B cells and monocytes (Figure 3B), while pSTAT1 did not significantly
240 correlate with Siglec-1 as a surrogate for IFN signature or e.g. age (Figure 3C). Also STAT1
241 and IRF9 both components of the ISGFR3 did not correlate (Figure 3C).

242 **3.5. Reduced STAT1 response upon IFN stimulation in severe COVID-19**

243 To further evaluate the functionality of type I and II IFN signaling in the context of our finding
244 of reduced baseline whole protein expression of STAT1, we stimulated PBMCs of healthy
245 controls, mildly and severely affected COVID-19 patients with low doses of either IFN- α or IFN- γ
246 for 48h. As a control unstimulated cells (RPMI) of each group were used. Stimulation with

247 IFN- α led to a transcriptional upregulation of STAT1 in CD3+ T cells and CD19+ B cells in
248 healthy controls and in mild COVID-19 cases in CD19+ B cells (Fig 4A). In severe COVID-19
249 cases, a tendency of upregulation of STAT1 was observed (Figure 4A). The phosphorylation
250 of STAT1 after low dose IFN- α or IFN- γ stimulation for 48 hours remained unchanged in
251 healthy controls and mildly affected COVID-19 patients, while its was enhanced in severely
252 affected COVID-19 patients already in unstimulated cells and without further increase after 48h
253 incubation with IFN- α or IFN- γ (Figure 4B). Short term stimulation with higher doses of IFN- α
254 was not able to increase pSTAT1 in severe COVID-19 cases. IFN- γ stimulation did not impact
255 STAT1 phosphorylation (Figure 4C).

256

257 **4. Discussion**

258 COVID-19 is characterized by excessive production of multiple pro-inflammatory cytokines [21,
259 22] and patients with severe COVID-19 have a highly impaired IFN type I signature, in
260 particular reduced IFN- α production and activity [6]. A common signaling route of cytokines,
261 including IFNs is the JAK STAT signaling pathway [23]. JAKs and STATs provide a highly
262 complex but orchestrated system of heterogeneous molecules with specific signaling through
263 defined receptor complexes including recruitment of different STATs and resulting in specific
264 downstream transcription [7].

265 In this study we describe an upregulation of STAT1 and IRF9 in mildly and severely affected
266 COVID-19 patients, which correlated with the IFN-signature reflected by Siglec-1 surface
267 expression. Both, Siglec-1 and STAT1 were lower among severely affected COVID-19 patients
268 compared to mildly affected COVID-19 patients, especially in plasmablasts and monocytes.
269 This is of particular interest since, these two cell types are considered the main players of
270 pathogenesis in severe COVID-19 [24, 25]. The data suggest that certain viral factors may limit
271 proper STAT1 and IRF9 function in severe COVID-19 patients in these cells and that the
272 inhibition of translocation of STATs is more pronounced than the inhibition of phosphorylation
273 [13, 14]. These results are in accordance with other authors, showing Siglec-1 expression
274 correlate with viral load in mild COVID patients, but in severe COVID patients [26].

275 Increased levels of STAT1 in B cells were previously reported in SLE patients which correlate
276 with Siglec-1 expression on CD14+ monocytes [18]. In a similar way, SLE patients have
277 increased levels of the STAT1 protein in CD4+ T cells, alteration associated with perturbed
278 homeostasis of regulatory T cells and disease severity [27]. Discordant to the whole protein
279 levels, the phosphorylation of STAT1 is enhanced in severely affected COVID-19 patients
280 suggesting a dysbalanced JAK STAT signaling that fails to induce transcription of the ISRE.
281 An increased pSTAT1 is also present without stimulation in cultured PBMCs (here CD19+ B
282 cells and CD3+ cells) and no further increase by IFN- α or IFN- γ stimulation is achieved.
283 Further, this intervention could not demonstrate a transcriptional increase of STAT1 which
284 would indicate reversibility of this condition.

285 Interestingly, phosphorylation of STAT1 in response to IFN stimulation can persist for hours,
286 but newly synthesized unphosphorylated STAT1 induced by pSTAT1 can persist for several
287 days [28]. This suggest high levels of unphosphorylated STAT1 in COVID patients were
288 synthesized in response to persistent type I IFN signaling. It is worth to note that cells treated
289 with lentivirus which exhibited increase in STAT1, did not completely phosphorylated in
290 response to IFN stimulation [29]. Data shows that the antiviral role of STAT1 is not completely
291 dependent of phosphorylation and suggests a role of alternative unphosphorylated STAT1
292 mediated pathways in COVID-19.

293 The reduced Siglec-1 expression on the surface of CD14+ monocytes of patients suffering
294 from severe COVID-19 compared to patients with mild COVID-19 is consistent with published
295 data [30-32]. As a result of this finding and efficient analysis of Siglec-1 (CD169) on CD14+

296 cells, we started to routinely measure Siglec-1 in all patients with COVID-19 admitted to ICUs
297 to distinguish between patients with high and low interferon signature to test the hypothesis of
298 an association of IFN signature and outcome of the patients.

299 Absence of correlation between STAT1 and pSTAT1 with IRF9, suggest that an alternative
300 IRF9 independent signaling [12] could have a role in COVID-19. Previously, it was reported for
301 IRF9 knock-out mice that type I IFN mediates a potent inflammatory response associated with
302 a more severe neurological disease [33]. Varicella zoster virus prevents type I IFN response
303 reducing IRF9 and inhibition of STAT2 phosphorylation in infected cells [34]. IRF9 also
304 prevents exhaustion of CD8+ T cells in Lymphocytic choriomeningitis infection [35].
305 Interestingly, SARS-CoV-2 spike transfected cells secrete miR-148a and -590 via exosomes
306 which induce degradation of IRF9 in human microglia [36].

307 Currently, optimal treatment for patients with COVID-19 is still uncertain and both interventions,
308 blocking of IFN signaling by JAK STAT inhibition [37, 38] or the use of different types of IFN
309 as substitutions have been suggested as a treatment for COVID-19 and showed efficacy in
310 small clinical trials [39, 40]. Thus, the key question raises which intervention is appropriate for
311 which patient? In patients with high IFN signaling that are likely in an early stage of the disease,
312 inhibition strategies appear to be attractive especially during the phase of cytokine storm. On
313 the other hand, patients with inability to increase antiviral response are likely in severe stage
314 of disease, IFN substitution may hold more promise than further inhibition.

315 The current data indicate severe impairment of STAT1 and IRF9 in severely infected COVID-
316 19 patients consistent with inappropriate type IFN upregulation as a potential mechanism for
317 enhanced disease severity. It appears of utmost importance to understand the underlying
318 mechanisms in more detail as patients with diminished type IFN response may benefit from
319 targeted therapies. In this regard, JAK STAT inhibition may hold promise for patients with
320 higher STAT1 expression (mild cases), while patients with low Siglec-1 and unable inability to
321 increase antiviral response may benefit from IFN substitution.

322 **5. Conflict of Interest Statement**

323 The authors declare that the research was conducted in the absence of any commercial or
324 financial relationships that could be construed as a potential conflict of interest.

325

326 **6. Ethics Statement**

327 This study was carried out in accordance with the recommendations of the ethics' committees
328 at the Charité University Hospital Berlin and University of Ulm with written informed consent
329 from all subjects. All subjects gave written informed consent in accordance with the Declaration
330 of Helsinki.

331

332 **7. Author Contributions**

333

334 ES, AA, JR, DK, DZ and LS enrolled patients and collected samples.
335 HR, ES, FSZ, LS and AA analyzed the data.
336 SK, HS provided patients within the clinical trial.
337 KUE, TD, AL, ES and HS supervised the work and acquired funding

338 All authors developed, read, and approved the current manuscript.

339 **8. Funding**

340 ES was funded by the Federal Ministry of Education and Research (BMBF) grant BCOVIT,
341 01KI20161. ES received a grant by the Berlin Institute of Health with the Charité Clinician
342 Scientist Program funded by the Charité –Universitätsmedizin Berlin and the Berlin Institute of
343 Health. ALS is funded by a scholarship of the German Society of Rheumatology. TD is
344 grantholder of the Deutsche Forschungsgemeinschaft grants KO 2270/7 1, KO-2270/4-1 (KK);
345 Do491/7-5, 11-1, Transregio 130 TP24. HRA holds a scholarship of the COLCIENCIAS
346 scholarship No. 727, 2015. The CAPSID trial was funded by the German Federal Ministry of
347 Health (Bundesministerium für Gesundheit) to HS and SK.

348 9. References

- 349 1 **Platanias, L. C.**, Mechanisms of type-I- and type-II-interferon-mediated signalling.
350 *Nat Rev Immunol* 2005. **5**: 375-386.
- 351 2 **Vivier, E., Tomasello, E., Baratin, M., Walzer, T. and Ugolini, S.**, Functions of
352 natural killer cells. *Nat Immunol* 2008. **9**: 503-510.
- 353 3 **Bonjardim, C. A.**, Interferons (IFNs) are key cytokines in both innate and adaptive
354 antiviral immune responses--and viruses counteract IFN action. *Microbes Infect* 2005.
355 **7**: 569-578.
- 356 4 **Bastard, P., Rosen, L. B., Zhang, Q., Michailidis, E., Hoffmann, H. H., Zhang, Y.,**
357 **Dorgham, K., Philippot, Q., Rosain, J., Beziat, V., Manry, J., Shaw, E.,**
358 **Haljasmagi, L., Peterson, P., Lorenzo, L., Bizien, L., Trouillet-Assant, S., Dobbs,**
359 **K., de Jesus, A. A., Belot, A., Kallaste, A., Catherinot, E., Tandjaoui-Lambiotte,**
360 **Y., Le Pen, J., Kerner, G., Bigio, B., Seeleuthner, Y., Yang, R., Bolze, A., Spaan,**
361 **A. N., Delmonte, O. M., Abers, M. S., Aiuti, A., Casari, G., Lampasona, V.,**
362 **Piemonti, L., Ciceri, F., Bilguvar, K., Lifton, R. P., Vasse, M., Smadja, D. M.,**
363 **Migaud, M., Hadjadj, J., Terrier, B., Duffy, D., Quintana-Murci, L., van de Beek,**
364 **D., Roussel, L., Vinh, D. C., Tangye, S. G., Haerynck, F., Dalmau, D., Martinez-**
365 **Picado, J., Brodin, P., Nussenzweig, M. C., Boisson-Dupuis, S., Rodriguez-**
366 **Gallego, C., Vogt, G., Mogensen, T. H., Oler, A. J., Gu, J., Burbelo, P. D., Cohen,**
367 **J. I., Biondi, A., Bettini, L. R., D'Angio, M., Bonfanti, P., Rossignol, P., Mayaux,**
368 **J., Rieux-Laucat, F., Husebye, E. S., Fusco, F., Ursini, M. V., Imberti, L., Sottini,**
369 **A., Paghera, S., Quiros-Roldan, E., Rossi, C., Castagnoli, R., Montagna, D.,**
370 **Licari, A., Marseglia, G. L., Duval, X., Ghosn, J., Lab, H., Group, N.-U. I. R. t. C.,**
371 **Clinicians, C., Clinicians, C.-S., Imagine, C. G., French, C. C. S. G., Milieu**
372 **Interieur, C., Co, V. C. C., Amsterdam, U. M. C. C.-B., Effort, C. H. G., Tsang, J.**
373 **S., Goldbach-Mansky, R., Kisand, K., Lionakis, M. S., Puel, A., Zhang, S. Y.,**
374 **Autoantibodies against type I IFNs in patients with life-threatening COVID-19.**
375 *Science* 2020. **370**.
- 376 5 **Zhang, Q., Bastard, P., Liu, Z., Le Pen, J., Moncada-Velez, M., Chen, J., Ogishi,**
377 **M., Sabli, I. K. D., Hodeib, S., Korol, C., Rosain, J., Bilguvar, K., Ye, J., Bolze, A.,**
378 **Bigio, B., Yang, R., Arias, A. A., Zhou, Q., Zhang, Y., Onodi, F., Korniotis, S.,**
379 **Karpf, L., Philippot, Q., Chbihi, M., Bonnet-Madin, L., Dorgham, K., Smith, N.,**
380 **Schneider, W. M., Razooky, B. S., Hoffmann, H. H., Michailidis, E., Moens, L.,**
381 **Han, J. E., Lorenzo, L., Bizien, L., Meade, P., Neehus, A. L., Ugurbil, A. C.,**
382 **Corneau, A., Kerner, G., Zhang, P., Rapaport, F., Seeleuthner, Y., Manry, J.,**
383 **Masson, C., Schmitt, Y., Schluter, A., Le Voyer, T., Khan, T., Li, J., Fellay, J.,**
384 **Roussel, L., Shahrooei, M., Alosaimi, M. F., Mansouri, D., Al-Saud, H., Al-Mulla,**
385 **F., Almourfi, F., Al-Muhsen, S. Z., Alsohime, F., Al Turki, S., Hasanato, R., van de**
386 **Beek, D., Biondi, A., Bettini, L. R., D'Angio, M., Bonfanti, P., Imberti, L., Sottini,**
387 **A., Paghera, S., Quiros-Roldan, E., Rossi, C., Oler, A. J., Tompkins, M. F., Alba,**
388 **C., Vandernoot, I., Goffard, J. C., Smits, G., Migeotte, I., Haerynck, F., Soler-**
389 **Palacin, P., Martin-Nalda, A., Colobran, R., Morange, P. E., Keles, S., Colkesen,**
390 **F., Ozcelik, T., Yasar, K. K., Senoglu, S., Karabela, S. N., Rodriguez-Gallego, C.,**
391 **Novelli, G., Hraiech, S., Tandjaoui-Lambiotte, Y., Duval, X., Laouenan, C.,**
392 **Clinicians, C.-S., Clinicians, C., Imagine, C. G., French, C. C. S. G., Inborn errors**
393 **of type I IFN immunity in patients with life-threatening COVID-19. Science** 2020. **370**.

- 394 6 **Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Pere, H.,**
395 **Charbit, B., Bondet, V., Chenevier-Gobeaux, C., Breillat, P., Carlier, N., Gauzit,**
396 **R., Morbieu, C., Pene, F., Marin, N., Roche, N., Szwebel, T. A., Merklings, S. H.,**
397 **Treluyer, J. M., Veyer, D., Mouthon, L., Blanc, C., Tharaux, P. L., Rozenberg, F.,**
398 **Fischer, A., Duffy, D., Rieux-Laucat, F., Kerneis, S. and Terrier, B.,** Impaired type
399 I interferon activity and inflammatory responses in severe COVID-19 patients.
400 *Science* 2020. **369**: 718-724.
- 401 7 **Shuai, K., Ziemiecki, A., Wilks, A. F., Harpur, A. G., Sadowski, H. B., Gilman, M.**
402 **Z. and Darnell, J. E.,** Polypeptide signalling to the nucleus through tyrosine
403 phosphorylation of Jak and Stat proteins. *Nature* 1993. **366**: 580-583.
- 404 8 **Darnell, J. E., Jr., Kerr, I. M. and Stark, G. R.,** Jak-STAT pathways and
405 transcriptional activation in response to IFNs and other extracellular signaling
406 proteins. *Science* 1994. **264**: 1415-1421.
- 407 9 **Banninger, G. and Reich, N. C.,** STAT2 nuclear trafficking. *J Biol Chem* 2004. **279**:
408 39199-39206.
- 409 10 **Paul, A., Tang, T. H. and Ng, S. K.,** Interferon Regulatory Factor 9 Structure and
410 Regulation. *Front Immunol* 2018. **9**: 1831.
- 411 11 **Platanitis, E., Demiroz, D., Schneller, A., Fischer, K., Capelle, C., Hartl, M.,**
412 **Gossenreiter, T., Muller, M., Novatchkova, M. and Decker, T.,** A molecular switch
413 from STAT2-IRF9 to ISGF3 underlies interferon-induced gene transcription. *Nat*
414 *Commun* 2019. **10**: 2921.
- 415 12 **Michalska, A., Blaszczyk, K., Wesoly, J. and Bluysen, H. A. R.,** A Positive
416 Feedback Amplifier Circuit That Regulates Interferon (IFN)-Stimulated Gene
417 Expression and Controls Type I and Type II IFN Responses. *Front Immunol* 2018. **9**:
418 1135.
- 419 13 **Wu, Y., Ma, L., Zhuang, Z., Cai, S., Zhao, Z., Zhou, L., Zhang, J., Wang, P. H.,**
420 **Zhao, J. and Cui, J.,** Main protease of SARS-CoV-2 serves as a bifunctional
421 molecule in restricting type I interferon antiviral signaling. *Signal Transduct Target*
422 *Ther* 2020. **5**: 221.
- 423 14 **Lei, X., Dong, X., Ma, R., Wang, W., Xiao, X., Tian, Z., Wang, C., Wang, Y., Li, L.,**
424 **Ren, L., Guo, F., Zhao, Z., Zhou, Z., Xiang, Z. and Wang, J.,** Activation and evasion
425 of type I interferon responses by SARS-CoV-2. *Nat Commun* 2020. **11**: 3810.
- 426 15 **Dodd, L. E., Follmann, D., Wang, J., Koenig, F., Korn, L. L., Schoergenhofer, C.,**
427 **Proschan, M., Hunsberger, S., Bonnett, T., Makowski, M., Belhadi, D., Wang, Y.,**
428 **Cao, B., Mentre, F. and Jaki, T.,** Endpoints for randomized controlled clinical trials
429 for COVID-19 treatments. *Clin Trials* 2020. **17**: 472-482.
- 430 16 **Kurth, F., Roenefarth, M., Thibeault, C., Corman, V. M., Muller-Redetzky, H.,**
431 **Mittermaier, M., Ruwwe-Glosenkamp, C., Heim, K. M., Krannich, A., Zvorc, S.,**
432 **Schmidt, S., Kretzler, L., Dang-Heine, C., Rose, M., Hummel, M., Hocke, A.,**
433 **Hubner, R. H., Opitz, B., Mall, M. A., Rohmel, J., Landmesser, U., Pieske, B.,**
434 **Knauss, S., Endres, M., Spranger, J., Mockenhaupt, F. P., Tacke, F., Treskatsch,**
435 **S., Angermair, S., Siegmund, B., Spies, C., Weber-Carstens, S., Eckardt, K. U.,**
436 **Schurmann, D., Uhrig, A., Stegemann, M. S., Zoller, T., Drosten, C., Suttorp, N.,**
437 **Witzenrath, M., Hippenstiel, S., von Kalle, C. and Sander, L. E.,** Studying the
438 pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective
439 COVID-19 patient cohort (Pa-COVID-19). *Infection* 2020. **48**: 619-626.
- 440 17 **Körper, S., Weiss, M., Zickler, D., Wiesmann, T., Zacharowski, K., M.Corman, V.,**
441 **Grüner, B., Ernst, L., Spieth, P., Lepper, P. M., Bentz, M., Zinn, S., Paul, G.,**
442 **Kalbhenn, J., Dollinger, M., Rosenberger, P., Kirschning, T., Thiele, T., Appl, T.,**
443 **Mayer, B., Schmidt, M., Drosten, C., Wulf, H., Kruse, J. M., Jungwirth, B.,**
444 **Seifried, E. and Schrezenmeier, H.,** High Dose Convalescent Plasma in COVID-19:
445 Results from the Randomized Trial CAPSID. *medRxiv* 2021:
446 2021.2005.2010.21256192.
- 447 18 **Aue, A., Szelinski, F., Weissenberg, S. Y., Wiedemann, A., Rose, T., Lino, A. C.**
448 **and Dorner, T.,** Elevated STAT1 expression but not phosphorylation in lupus B cells

- 449 correlates with disease activity and increased plasmablast susceptibility.
450 *Rheumatology (Oxford)* 2020. **59**: 3435-3442.
- 451 19 **Rose, T., Szelinski, F., Lisney, A., Reiter, K., Fleischer, S. J., Burmester, G. R.,**
452 **Radbruch, A., Hiepe, F., Grutzkau, A., Biesen, R. and Dorner, T.,** SIGLEC1 is a
453 biomarker of disease activity and indicates extraglandular manifestation in primary
454 Sjogren's syndrome. *RMD Open* 2016. **2**: e000292.
- 455 20 **Biesen, R., Demir, C., Barkhudarova, F., Grun, J. R., Steinbrich-Zollner, M.,**
456 **Backhaus, M., Haupl, T., Rudwaleit, M., Riemekasten, G., Radbruch, A., Hiepe,**
457 **F., Burmester, G. R. and Grutzkau, A.,** Sialic acid-binding Ig-like lectin 1 expression
458 in inflammatory and resident monocytes is a potential biomarker for monitoring
459 disease activity and success of therapy in systemic lupus erythematosus. *Arthritis*
460 *Rheum* 2008. **58**: 1136-1145.
- 461 21 **Lucas, C., Wong, P., Klein, J., Castro, T. B. R., Silva, J., Sundaram, M.,**
462 **Ellingson, M. K., Mao, T., Oh, J. E., Israelow, B., Takahashi, T., Tokuyama, M.,**
463 **Lu, P., Venkataraman, A., Park, A., Mohanty, S., Wang, H., Wyllie, A. L., Vogels,**
464 **C. B. F., Earnest, R., Lapidus, S., Ott, I. M., Moore, A. J., Muenker, M. C.,**
465 **Fournier, J. B., Campbell, M., Odio, C. D., Casanovas-Massana, A., Yale, I. T.,**
466 **Herbst, R., Shaw, A. C., Medzhitov, R., Schulz, W. L., Grubaugh, N. D., Dela**
467 **Cruz, C., Farhadian, S., Ko, A. I., Omer, S. B. and Iwasaki, A.,** Longitudinal
468 analyses reveal immunological misfiring in severe COVID-19. *Nature* 2020. **584**: 463-
469 469.
- 470 22 **Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., Manson, J. J.**
471 **and Hlh Across Speciality Collaboration, U. K.,** COVID-19: consider cytokine
472 storm syndromes and immunosuppression. *Lancet* 2020. **395**: 1033-1034.
- 473 23 **Salas, A., Hernandez-Rocha, C., Duijvestein, M., Faubion, W., McGovern, D.,**
474 **Vermeire, S., Vetrano, S. and Vande Casteele, N.,** JAK-STAT pathway targeting for
475 the treatment of inflammatory bowel disease. *Nat Rev Gastroenterol Hepatol* 2020.
476 **17**: 323-337.
- 477 24 **Ferreira-Gomes, M., Kruglov, A., Durek, P., Heinrich, F., Tizian, C., Heinz, G. A.,**
478 **Pascual-Reguant, A., Du, W., Mothes, R., Fan, C., Frischbutter, S., Habenicht, K.,**
479 **Budzinski, L., Ninnemann, J., Jani, P. K., Guerra, G. M., Lehmann, K., Matz, M.,**
480 **Ostendorf, L., Heiberger, L., Chang, H. D., Bauherr, S., Maurer, M., Schonrich,**
481 **G., Raftery, M., Kallinich, T., Mall, M. A., Angermair, S., Treskatsch, S., Dorner,**
482 **T., Corman, V. M., Diefenbach, A., Volk, H. D., Elezkurtaj, S., Winkler, T. H.,**
483 **Dong, J., Hauser, A. E., Radbruch, H., Witkowski, M., Melchers, F., Radbruch, A.**
484 **and Mashreghi, M. F.,** SARS-CoV-2 in severe COVID-19 induces a TGF-beta-
485 dominated chronic immune response that does not target itself. *Nat Commun* 2021.
486 **12**: 1961.
- 487 25 **Kosyreva, A., Dzhaliilova, D., Lokhonina, A., Vishnyakova, P. and Fatkhudinov,**
488 **T.,** The Role of Macrophages in the Pathogenesis of SARS-CoV-2-Associated Acute
489 Respiratory Distress Syndrome. *Front Immunol* 2021. **12**: 682871.
- 490 26 **Doehn, J. M., Tabeling, C., Biesen, R., Saccomanno, J., Madlung, E., Pappe, E.,**
491 **Gabriel, F., Kurth, F., Meisel, C., Corman, V. M., Hanitsch, L. G., Treskatsch, S.,**
492 **Heim, K., Stegemann, M. S., Ruwwe-Glosenkamp, C., Muller-Redetzky, H. C.,**
493 **Uhrig, A., Somasundaram, R., Spies, C., von Bernuth, H., Hofmann, J., Drost, C.,**
494 **Suttorp, N., Witzernath, M., Sander, L. E. and Hubner, R. H.,** CD169/SIGLEC1
495 is expressed on circulating monocytes in COVID-19 and expression levels are
496 associated with disease severity. *Infection* 2021. **49**: 757-762.
- 497 27 **Goropevsek, A., Gorenjak, M., Gradisnik, S., Dai, K., Holc, I., Hojs, R., Krajnc, I.,**
498 **Pahor, A. and Avcin, T.,** Increased Levels of STAT1 Protein in Blood CD4 T Cells
499 from Systemic Lupus Erythematosus Patients Are Associated with Perturbed
500 Homeostasis of Activated CD45RA(-)FOXP3(hi) Regulatory Subset and Follow-Up
501 Disease Severity. *J Interferon Cytokine Res* 2017. **37**: 254-268.
- 502 28 **Lehtonen, A., Matikainen, S. and Julkunen, I.,** Interferons up-regulate STAT1,
503 STAT2, and IRF family transcription factor gene expression in human peripheral

- 504 blood mononuclear cells and macrophages. *The Journal of Immunology* 1997. **159**:
505 794-803.
- 506 29 **Cheon, H. and Stark, G. R.**, Unphosphorylated STAT1 prolongs the expression of
507 interferon-induced immune regulatory genes. *Proc Natl Acad Sci U S A* 2009. **106**:
508 9373-9378.
- 509 30 **Ortillon, M., Coudereau, R., Cour, M., Rimmele, T., Godignon, M., Gossez, M.,**
510 **Yonis, H., Argaud, L., Lukaszewicz, A. C., Venet, F. and Monneret, G.**, Monocyte
511 CD169 expression in COVID-19 patients upon intensive care unit admission.
512 *Cytometry A* 2021. **99**: 466-471.
- 513 31 **Bourgoin, P., Soliveres, T., Barbaresi, A., Loundou, A., Belkacem, I. A., Arnoux,**
514 **I., Bernot, D., Loosveld, M., Morange, P. E., Michelet, P., Malergue, F. and**
515 **Markarian, T.**, CD169 and CD64 could help differentiate bacterial from CoVID-19 or
516 other viral infections in the Emergency Department. *Cytometry A* 2021. **99**: 435-445.
- 517 32 **Bedin, A. S., Makinson, A., Picot, M. C., Mennechet, F., Malergue, F., Pisoni, A.,**
518 **Nyiramigisha, E., Montagnier, L., Bollore, K., Debieesse, S., Morquin, D.,**
519 **Veyrenche, N., Renault, C., Foulongne, V., Bret, C., Bourdin, A., Le Moing, V.,**
520 **Van de Perre, P. and Tuaille, E.**, Monocyte CD169 Expression as a Biomarker in
521 the Early Diagnosis of Coronavirus Disease 2019. *J Infect Dis* 2021. **223**: 562-567.
- 522 33 **Hofer, M. J., Li, W., Lim, S. L. and Campbell, I. L.**, The type I interferon-alpha
523 mediates a more severe neurological disease in the absence of the canonical
524 signaling molecule interferon regulatory factor 9. *The Journal of neuroscience : the*
525 *official journal of the Society for Neuroscience* 2010. **30**: 1149-1157.
- 526 34 **Verweij, M. C., Wellish, M., Whitmer, T., Malouli, D., Lapel, M., Jonjic, S., Haas, J.**
527 **G., DeFilippis, V. R., Mahalingam, R. and Fruh, K.**, Varicella Viruses Inhibit
528 Interferon-Stimulated JAK-STAT Signaling through Multiple Mechanisms. *PLoS*
529 *Pathog* 2015. **11**: e1004901.
- 530 35 **Huber, M., Suprunenko, T., Ashhurst, T., Marbach, F., Raifer, H., Wolff, S.,**
531 **Strecker, T., Viengkhou, B., Jung, S. R., Obermann, H. L., Bauer, S., Xu, H. C.,**
532 **Lang, P. A., Tom, A., Lang, K. S., King, N. J. C., Campbell, I. L. and Hofer, M. J.**,
533 IRF9 Prevents CD8(+) T Cell Exhaustion in an Extrinsic Manner during Acute
534 Lymphocytic Choriomeningitis Virus Infection. *J Virol* 2017. **91**.
- 535 36 **Mishra, R. and Banerjee, A. C.**, SARS-CoV-2 Spike Targets USP33-IRF9 Axis via
536 Exosomal miR-148a to Activate Human Microglia. *Front Immunol* 2021. **12**: 656700.
- 537 37 **Hayek, M. E., Mansour, M., Ndetan, H., Burkes, Q., Corkren, R., Dulli, A., Hayek,**
538 **R., Parvez, K. and Singh, S.**, Anti-Inflammatory treatment of COVID-19 pneumonia
539 with tofacitinib alone or in combination with dexamethasone is safe and possibly
540 superior to dexamethasone as a single agent in a predominantly African American
541 cohort. *Mayo Clin Proc Innov Qual Outcomes* 2021.
- 542 38 **Wijaya, I., Andhika, R., Huang, I., Purwiga, A., Budiman, K. Y., Bashari, M. H.,**
543 **Renianti, L. and Roesli, R. M. A.**, The use of Janus Kinase inhibitors in hospitalized
544 patients with COVID-19: Systematic review and meta-analysis. *Clin Epidemiol Glob*
545 *Health* 2021. **11**: 100755.
- 546 39 **Hung, I. F., Lung, K. C., Tso, E. Y., Liu, R., Chung, T. W., Chu, M. Y., Ng, Y. Y.,**
547 **Lo, J., Chan, J., Tam, A. R., Shum, H. P., Chan, V., Wu, A. K., Sin, K. M., Leung,**
548 **W. S., Law, W. L., Lung, D. C., Sin, S., Yeung, P., Yip, C. C., Zhang, R. R., Fung,**
549 **A. Y., Yan, E. Y., Leung, K. H., Ip, J. D., Chu, A. W., Chan, W. M., Ng, A. C., Lee,**
550 **R., Fung, K., Yeung, A., Wu, T. C., Chan, J. W., Yan, W. W., Chan, W. M., Chan, J.**
551 **F., Lie, A. K., Tsang, O. T., Cheng, V. C., Que, T. L., Lau, C. S., Chan, K. H., To, K.**
552 **K. and Yuen, K. Y.**, Triple combination of interferon beta-1b, lopinavir-ritonavir, and
553 ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-
554 label, randomised, phase 2 trial. *Lancet* 2020. **395**: 1695-1704.
- 555 40 **Andreakos, E. and Tsiodras, S.**, COVID-19: lambda interferon against viral load and
556 hyperinflammation. *EMBO Mol Med* 2020. **12**: e12465.

558 **Figure Legends**

559 **Figure 1 Reduced STAT1 expression in severe COVID-19 patients**

560 (A) Schematic depiction of JAK STAT signaling. (B) Gating strategy on whole blood flow
561 cytometry for IgD+CD27- (Naïve), IgD+CD27+ (PreSwitch), IgD-CD27+ (PostSwitched) and
562 IgD-CD27- (Double Negative, DN) as well as CD4+ and CD8+ T cells, (C) Representative
563 histograms of baseline expression of STAT1 on B cells from healthy controls (grey), mild
564 (blue) and severe (red) COVID-19 patients. (D) Median fluorescence intensity (MFI) of
565 STAT1 in CD3+, CD19+ and CD14+ cells. (E) MFI of STAT1 in T and B cell subsets (as
566 described in B). (F) Representative histograms of baseline expression of pSTAT1 on
567 B cells from healthy controls (grey), mild (blue) and severe (red) COVID-19 patients. (G)
568 MFI of STAT1 in CD3+, CD19+ and CD14+ cells. (H) MFI of pSTAT1 in T and
569 B cell subsets (as described in B). Median and data from healthy controls (n=20), mild COVID-
570 19 (n=17) and severe COVID-19 (n=13) patients. Two way ANOVA with Sidack post-test.
571 *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.

572 **Figure 2 Enhanced intracellular IRF9 expression in severe COVID-19**

573 (A) Representative histograms of baseline expression of IRF9 on B cells from healthy controls
574 (grey), mild (blue) and severe (red) COVID-
575 19 patients. (B) Median fluorescence intensity (MFI) of IRF9 in CD3+, CD19+ and
576 CD14+ cells. (C) MFI of IRF9 in T and B cell subsets (as described in
577 Fig1B). (D) Representative histograms of baseline expression of IRF1 on B cells healthy
578 controls (grey), mild (blue) and severe (red) COVID-19 patients. (E) MFI of IRF1 in CD3+,
579 CD19+ and CD14+ cells. (F) MFI of IRF1 in T and B cell subsets (as described in Figure
580 1B). (G) Representative histograms of baseline expression of IRF7 on B cells from healthy
581 controls (grey), mild (blue) and severe (red) COVID-19 patients. (H) MFI of IRF7 in CD3+,
582 CD19+ and CD14+ cells. (I) MFI of IRF7 in T and B cell subsets (as described in Figure
583 1B). Median and data from healthy controls (n=20), mild COVID-19 (n=17)
584 and severe COVID-19 (n=13) patients. Two way ANOVA with Sidack post-test. *p<0.05,
585 **p<0.01, ***p<0.001 and ****p<0.0001.

586 **Figure 3 Significant correlation of STAT1 and Siglec-1 (CD169)**

587 (A) Siglec-1 (CD169) expression on CD14+ monocytes in mild and severe COVID-19
588 patients. (B) Correlation of Siglec-1 expression on the surface of CD14+ monocytes with
589 intracellular STAT1 expression in CD3+ T cells, CD19+ B cells or CD14+ monocytes. Each
590 point represents a donor. Mann-Whitney U test. *p<0.05, **p<0.01. (C) Spearman's correlation
591 matrix showing the correlation of all investigated parameters (STAT1, pSTAT1, pSTAT2, IRF1,
592 IRF7 and IRF9) in relation to the analyzed cell populations (B cells, T cells and monocytes).
593 Corresponding correlations are represented by red (negative) or blue (positive) circles. Size
594 and intensity of color refer to the strength of correlation. Data from healthy controls (n=20),
595 mild COVID-19 (n=17) and severe COVID-19 (n=13) patients. Only correlations with $p \leq 0.05$
596 are indicated.

597 **Figure 4 Attenuated pSTAT1 response upon IFN type I and II stimulation in severe** 598 **COVID-19**

599 (A) STAT1 and (B) pSTAT1 expression in CD3+ T cells and CD19+ B cells in culture of PBMCs
600 from healthy controls (grey, n=8), mild (blue, n=9) or severe (red, n=7) COVID-19 patients.
601 Cells were stimulated for 48 hours with either IFN α (5ng/ml) or IFN γ (5ng/ml) or only RPMI as
602 a control. (C) PBMCs of the same donors as in (A) were stimulated with IFN α
603 (100ng/ml) or IFN γ (100ng/ml) for 5 minutes. Untreated control values of pSTAT1 were
604 subtracted to show the individual increase of STAT1 phosphorylation. Data is presented as

605 radar diagrams. Two way ANOVA with Sidack post-test. *p<0.05, **p<0.01, ***p<0.001 and
606 ****p<0.0001.

607

608 **Table 1: Patient characteristics**


609

	Mild COVID (n=17)	Severe COVID (n=13)	Healthy controls (n=20)
Age (median, IQR)	47.4 (34.0; 57.0)	61 (53.5; 69.5)	35 (29.0;47.0)
Female	7	1	14
Days post symptom onset	7 (10; 5.5)	10 (8.5; 15)	
Concomitant antibiotic treatment	0	6	
Immunosuppressive treatment before COVID	4	1	
Dexamethasone	0	12	
Tocilizumab	0	1	
Remdesivir	0	1	
CRP mg/dl	n.a.	116 (85.75; 188)	
WHO Ordinal scale 1	2		
WHO Ordinal scale 2	15		
WHO Ordinal scale 5		6	
WHO Ordinal scale 6		1	
WHO Ordinal scale 8		6	


610

Fig 1


A




B




C



D




E




Healthy controls
Mild COVID-19
Severe COVID-19


F



G




H




Healthy controls
Mild COVID-19
Severe COVID-19

Fig 4


A



B



C






Fig. S1 Intracellular pSTAT2 levels and pSTAT1/STAT1 ratio of HD and COVID-19 patients

(A) Ratio of pSTAT1/STAT1 in CD3+, CD19+ and CD14+ cells. Ratio of pSTAT1/STAT1 in T and B cell subsets (as described in Fig1B). **(B)** Median fluorescence intensity (MFI) of pSTAT2 in CD3+, CD19+ and CD14+ cells. MFI of pSTAT2 in T and B cell subsets (as described in Figure 1B). Median and data from HD (n=21), mild COVID-19 (n=17) and severe COVID-19 (n=13) patients. Two way ANOVA with Sidack post-test. *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.